China
Africa
Explore chapters and articles related to this topic
Archaeosomes for Skin Injuries
Published in Andreia Ascenso, Sandra Simões, Helena Ribeiro, Carrier-Mediated Dermal Delivery, 2017
Monica Vazzana, Joana F. Fangueiro, Caterina Faggio, Antonello Santini, Eliana B. Souto
Umalkar et al. formulated and evaluated ultradeformable vesicles gel of diflorasone diacetate, a corticosteroid, for topical application, prepared by using soya phosphatidylcholine and four different surfactants, i.e., Span 80, Tween 80, Sodium cholate, Span 60 by the lipid film hydration method, showing effectiveness in the treatment of psoriasis [46].
Tazarotene
Published in John Y. M. Koo, Ethan C. Levin, Argentina Leon, Jashin J. Wu, Mark G. Lebwohl, Mild to Moderate Psoriasis, 2014
Monica Huynh, Chai Sue Lee, John Y. M. Koo
Not only do tazarotene and topical steroid act synergistically but also tazarotene reduces the degree of topical steroid-induced skin atrophy [26]. In a study involving 24 healthy volunteers, subjects were randomized to apply 0.1% tazarotene gel, 0.05% diflorasone diacetate (Psorcon®), and 0.1% tazarotene gel combined with 0.05% diflorasone diacetate six days/week for four weeks [26]. The subjects who applied 0.1% tazarotene gel had a mean epidermal thickness increase of 62%. The subjects who applied 0.05% diflorasone diacetate experienced a 43% reduction in the mean epidermal thickness. However, in the subjects who used tazarotene in combination with 0.05% diflorasone diacetate, there was only a reduction of 28% in the epidermal thickness. Thus, tazarotene significantly reduced epidermal atrophy induced by topical steroid.
Topical Agents
Published in John Y. M. Koo, Ethan C. Levin, Argentina Leon, Jashin J. Wu, Alice B. Gottlieb, Moderate to Severe Psoriasis, 2014
Rosemary deShazo, Gerald G. Krueger, Kristina Callis Duffin
Tape Applied once daily, flurandrenolide tape (Cordran® tape) has been shown to produce >75% improvement in 64% of patients over four weeks and has been found to be superior to diflorasone diacetate ointment applied twice daily over four weeks [14]. This vehicle is particularly useful in the treatment of more lichenified plaques.
Healthcare resource utilization, costs of care, and treatment of mycosis fungoides cutaneous T-cell lymphoma patterns in a large managed care population: a retrospective US claims-based analysis
Published in Journal of Dermatological Treatment, 2018
Yuen Tsang, Tao Gu, Gaurav Sharma, Susan Raspa, Bill Drake, Hiangkiat Tan
MF-CTCL-specific index treatments were identified within 60 days following the index date. The first category based on a descending priority approach included MF-CTCL-specific drugs: systemic prednisone (dose adjusted), systemic chemotherapy (methotrexate ≤100 mg weekly, temozolomide, vincristine), interferons, systemic retinoids (bexarotene, tretinoin, isotretinoin) and vorinostat, among others. Next were skin-directed MF-CTCL-specific drugs other than topical corticosteroids: topical chemotherapy (mechlorethamine, carmustine), topical bexarotene and topical imiquimod. These were followed by topical corticosteroids: halobetasol, diflorasone, mometasone, halcinonide, desoximetasone, hydrocortisone, desonide, clobetasol, betamethasone, fluocinonide, flurandrenolide, triamcinolone, fluticasone. The final category, MF-CTCL-specific nondrug therapies included another class of index treatments such as local radiation, total skin electron beam therapy (TSEBT), psoralen plus ultraviolet A phototherapy (PUVA), ultraviolet B phototherapy (UVB) and extracorporeal photopheresis (ECP).